Last reviewed · How we verify
NCT00271622
The Neurodevelopmental and Behavioral Phenotyping Screening Protocol
trial in Neurologic Disorders in 5,000 participants. Currently enrolling.
Quick facts
| Lead sponsor | National Institute of Mental Health (NIMH) |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 27 February 2006 |
| Sites | 1 location across United States |
Conditions studied
- Neurologic Disorders — all drugs for Neurologic Disorders →
- Autism — all drugs for Autism →
- Neurodegenerative Disease — all drugs for Neurodegenerative Disease →
- Neurobehavioral Manifestation — all drugs for Neurobehavioral Manifestation →
Sponsor
National Institute of Mental Health (NIMH)
Who can join
6 Weeks and older, any sex, with Neurologic Disorders or Autism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this protocol is to allow for the careful evaluation of healthy volunteers and individuals with risk for psychiatric disorders or neurodevelopmental disorders, such as autism spectrum disorder for specific protocols at NIH....
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Identification of Developmental and Behavioral Markers Associated With Genetic Abnormalities in Autism Spectrum Disorder.
Bishop SL, Farmer C, Bal V, Robinson EB, et al · · 2017 · cited 77× · PMID 28253736 · DOI 10.1176/appi.ajp.2017.16101115 -
Concurrent validity of the differential ability scales, second edition with the Mullen Scales of Early Learning in young children with and without neurodevelopmental disorders.
Farmer C, Golden C, Thurm A. · · 2016 · cited 61× · PMID 25833070 · DOI 10.1080/09297049.2015.1020775 -
Concordance of the Vineland Adaptive Behavior Scales, second and third editions.
Farmer C, Adedipe D, Bal VH, Chlebowski C, et al · · 2020 · cited 59× · PMID 31657503 · DOI 10.1111/jir.12691 -
Convergent and divergent validity of the Mullen Scales of Early Learning in young children with and without autism spectrum disorder.
Swineford LB, Guthrie W, Thurm A. · · 2015 · cited 55× · PMID 25894712 · DOI 10.1037/pas0000116 -
The Early Screening for Autism and Communication Disorders: Field-testing an autism-specific screening tool for children 12 to 36 months of age.
Wetherby AM, Guthrie W, Hooker JL, Delehanty A, et al · · 2021 · cited 22× · PMID 33962531 · DOI 10.1177/13623613211012526 -
NIH Toolbox Cognition Battery Feasibility in Individuals With Williams Syndrome.
Condy EE, Becker L, Farmer C, Kaat AJ, et al · · 2022 · cited 5× · PMID 36306408 · DOI 10.1352/1944-7558-127.6.473 -
In-depth profile analysis and developmental trends in Wechsler performance among individuals with Williams syndrome.
Farmer C, Klein-Tasman BP, Chun A, Giserman-Kiss I, et al · · 2025 · PMID 41431786 · DOI 10.1080/09297049.2025.2603410 -
The Developmental Landscape of Children With Uveal Coloboma and Its Relationship With Clinical Phenotype and Genetics.
Brooks BP, Hehn AT, Blain D, Farmer C, et al · · 2026 · PMID 41248874 · DOI 10.1016/j.ajo.2025.11.011
Verify or expand the search:
- PubMed search for NCT00271622
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neurologic Disorders
Currently open trials in the same condition.
- NCT04684602 — Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions · Phase 1, PHASE2 · recruiting
- NCT00060541 — Evaluation and Treatment of Neurosurgical Disorders · recruiting
Other National Institute of Mental Health (NIMH) trials
Trials by the same sponsor.
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT05652465 — Transcranial Magnetic Stimulation for Youth With Treatment-Resistant Major Depressive Disorder · Phase 2 · suspended
- NCT07027839 — Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B) · Phase 1 · recruiting
- NCT06920628 — PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 In · Phase 1 · recruiting
- NCT06874205 — Assessment of 11C-JMJ-129 for Imaging PDE4D in Brain and Whole Body of Healthy Volunteers · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00271622 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute of Mental Health (NIMH)
- Last refreshed: 14 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00271622.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing